GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Channel Therapeutics Corp (AMEX:CHRO) » Definitions » Other Net Income (Loss)

CHRO (Channel Therapeutics) Other Net Income (Loss) : $0.00 Mil (TTM As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Channel Therapeutics Other Net Income (Loss)?

Channel Therapeutics's Other Net Income (Loss) for the three months ended in Dec. 2024 was $0.00 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00 Mil.

Channel Therapeutics Other Net Income (Loss) Historical Data

The historical data trend for Channel Therapeutics's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Channel Therapeutics Other Net Income (Loss) Chart

Channel Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Other Net Income (Loss)
- - - - -

Channel Therapeutics Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Other Net Income (Loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Channel Therapeutics Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Channel Therapeutics Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Channel Therapeutics's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Channel Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Channel Therapeutics Corp (AMEX:CHRO) » Definitions » Other Net Income (Loss)
Comparable Companies
MTVA CYCN PMCB SLXN TSBX INTS CTXR APRE TRAW HCWB VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
4400 Route 9 South, Suite 1000, Freehold, NJ, USA, 07728
Website
https://www.channeltherapeutics.com
Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic, visceral pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.